Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 26 of 6351
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis is a phase 2, open-label, multicenter study evaluating the efficacy and safety of a fixed-duration combination of epcoritamab, venetoclax, and ibrutinib (EVI) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who hav…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Hope for kids with tough cancer: new combo trial launches
Disease control Not yet recruitingPatients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will…
Phase 2 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Engineered immune cells take on aggressive lymphomas in new trial
Disease control Not yet recruitingThis clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a diabetes drug slow Parkinson's? a trial puts it to the test
Disease control Not yet recruitingParkinson's disease (PD) is a progressive neurodegenerative disorder pathologically characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of α-synuclein (α-syn) aggregates. To date, all approved treatments, including levodopa…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A pill that could replace infusions for a rare blood disease?
Disease control Not yet recruitingAn open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protoc…
Phase 3 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for hodgkin lymphoma: drug combo could replace chemo in relapsed patients
Disease control Not yet recruitingThis phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improv…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a pill target a Hard-to-Treat colorectal cancer?
Disease control Not yet recruitingThis study is conducted sequentially in 3 parts. The primary objective for Part 1 is to determine the maximum tolerated dose of DES-1357 in participants with confirmed dMMR/MSI-H colorectal cancer (CRC). The primary objective for Part 2 is to assess the chronic tolerability and t…
Phase 1/2 • Sponsor: D. E. Shaw Research, LLC • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a repurposed drug slow rare childhood brain diseases?
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, tolerability and clinical activity of PLX-200 in pediatric patients with lysosomal storage disorders.
Phase 2 • Sponsor: Polaryx Therapeutics, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new pill take on brain cancer?
Disease control Not yet recruitingThis is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diag…
Phase 1 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Patient's own immune cells be supercharged to fight ovarian cancer?
Cure Not yet recruitingPatients with recurrent ovarian cancer will undergo resection of a safely accessible metastatic lesion, from which tumor-infiltrating lymphocytes (TIL) will be cultured, metabolically reprogrammed for metabolic fit T cells, then selected for CD137+ activated T cells, and then exp…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length…
Phase 3 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a diabetes drug shield the hearts of people with schizophrenia?
Disease control Not yet recruitingPatients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. This multicentre, double-blind, placebo-controlled randomised trial evaluates whether adjunctive oral s…
Phase 3 • Sponsor: All India Institute of Medical Sciences, Bhubaneswar • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a drug plus surgery heal Crohn's fistulas for good?
Disease control Not yet recruitingThis Phase 4, single-arm, open-label study will evaluate the effectiveness and safety of mirikizumab combined with surgical curettage and closure in adults with active perianal fistulizing Crohn's disease. Fifty participants with complex draining fistulas will undergo staged surg…
Phase 4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a daily pill help chinese adults with obesity shed pounds?
Disease control Not yet recruitingThe purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Psychedelic-Assisted therapy help veterans with PTSD?
Symptom relief Not yet recruitingThis study will evaluate the feasibility, safety and preliminary efficacy of psilocybin-assisted psychotherapy in military veterans with treatment-refractory posttraumatic stress disorder (PTSD).
Phase 2 • Sponsor: ARQ National Psychotrauma Centre • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can a new ablation technique quiet dangerous heart rhythms?
Disease control Not yet recruitingThe VERITAS VT Study is a prospective, multicenter, international, single-arm clinical investigation designed to evaluate the safety and effectiveness of the FieldForce™ Pulsed Field Ablation System for the treatment of sustained monomorphic ventricular tachycardia (VT). Eligible…
Sponsor: Field Medical • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a blood thinner plus progesterone prevent recurrent miscarriages?
Disease control Not yet recruitingThe objective of the trial is to assess whether the combination of enoxaparine (LMWH) with progesterone increases the live birth rate compared to standard of care (no active treatment) in women with unexplained recurrent pregnancy loss.
Phase 3 • Sponsor: General University Hospital, Prague • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
New combo aims to outdo standard chemo for FLT3-Mutated leukemia
Disease control Not yet recruitingThis international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction plus a FLT3inhibitor (quizartinib or midostaurin) (co…
Phase 2/3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
Disease control Not yet recruitingThe primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.
Phase 3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can two arthritis drugs stop deadly brain seizures? major trial launches
Disease control Not yet recruitingThe goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus). NORSE causes continuous seizures in previously health…
Phase 3 • Sponsor: Yale University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC